Sitagliptin 100 mg Tablets (Sitagliptin Phosphate Monohydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.
MFDS item code 201503238 · Approved 2015.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to assist in blood sugar control in patients with type 2 diabetes. It can be administered alone to patients who are being treated for the first time. If blood sugar control is difficult with monotherapy, it is combined with metformin. Additionally, if there is insufficient effect with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this drug can be added. When it is difficult to control blood sugar even when using multiple medications together, adding this medication can enhance the therapeutic effect. It is used in various situations to improve blood sugar control.
This drug is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered without regard to the timing of dialysis.
This medication is used to treat diabetes and helps to control blood sugar. The most important caution while taking this medication is that allergic reactions may occur. Some patients may experience serious allergic reactions such as anaphylaxis, angioedema, or severe skin conditions, so if symptoms like rash or difficulty breathing occur within three months of taking it, use should be stopped immediately and a medical consultation should be sought. Moreover, this medication can cause a condition called pancreatitis, which is inflammation of the pancreas; therefore, if symptoms such as abdominal pain, nausea, or vomiting indicating pancreatitis occur, the medication should be discontinued immediately and medical consultation should be obtained. Patients with type 1 diabetes, diabetic ketoacidosis, or those with a history of severe allergic reactions to this drug or its components should not take this medication. Patients with impaired kidney function may have delayed excretion of this medication, thus dosage adjustment is necessary, and regular kidney function tests should be conducted before and during treatment. Side effects that may occur when taking this medication alone or in combination with other diabetes medications include upper respiratory infections, nasopharyngitis, headache, and diarrhea. Particularly, when taken with sulfonylureas or insulin, the risk of hypoglycemia may increase, so blood sugar levels should be monitored carefully. Pregnant or breastfeeding women are advised against using this medication, and safety and effectiveness in pediatric patients under 18 have not been established. Elderly patients may have a higher likelihood of reduced kidney function, thus dosage adjustments and monitoring of kidney function are necessary. In case of overdose, general symptomatic treatment is recommended, and if necessary, some medications can be removed by hemodialysis. This medication has relatively low risk of interactions with other drugs; however, caution is necessary when taken together with cyclosporine or digoxin, so all medications being taken should be disclosed to healthcare personnel. Finally, if joint pain or skin blisters occur during the use of this medication, inform healthcare personnel immediately, and consider stopping the medication if these symptoms arise.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia with severe and disabling symptoms, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, increased low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.
Beige, round, biconvex film-coated tablets
28 tablets/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.